Isomorphic Labs President Max Jaderberg says artificial intelligence will eventually be used to develop all medicines, and that the open question is how soon that will happen.
Isomorphic Labs · Max Jaderberg
AI will develop all medicines. The open question is how soon.
Isomorphic Labs President Max Jaderberg frames AI as central to drug development, not peripheral to it. His remark is a forecast, not a product launch, clinical result or timeline.
The debate
Two readings of the same forecast
Supporters point to
Growing use of machine learning to predict molecular structures
Wider use of AI to screen candidate compounds
Genuine technical direction behind the strategic positioning
Skeptics point to
Computational predictions must still be validated in labs and human trials
Regulatory approval stays lengthy, however a drug was discovered
Drug development has long been slow, costly and prone to failure
The path to proof
What would test the prediction
1. AI-designed candidate
Molecule predicted and designed by AI systems
→
2. Laboratory validation
Predictions checked against real experiments
→
3. Clinical testing
Candidates move through human trials
→
4. Regulatory approval
Lengthy review, regardless of discovery method
Key indicators
Until the evidence accumulates, this remains a belief about the future of medicine.
Clinical progress
Do AI-designed candidates move through clinical testing?
Success rates
Do they outperform conventional approaches?
Continue reading The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in ✓ Signed in — this article isn’t included in your current plan.Unlocking the full article...